DURHAM, N.C., September 16, 2016 — Premier Research has named Dr. Howard Welgus Medical Director to lead dermatology research, building on the company’s existing dermatology study offerings to innovative biopharmaceutical companies. Dr. Welgus brings to this new role extensive experience in pharmaceutical research and development and academia.
Dr. Welgus has supported the development efforts of several companies through his own R&D consultancy company. He previously was Chief Medical Officer at Nycomed US, Vice President and Head of Dermatology and Inflammation at Pfizer Global R&D, and Senior Director for Inflammation Pharmacology at Pfizer.
He taught dermatology in medicine at the Washington University School of Medicine in St. Louis for 18 years. Dr. Welgus also led the Division of Dermatology at Jewish Hospital of Washington University and oversaw the Division of Dermatology at the VA medical Center of St. Louis.
Dr. Welgus received a medical degree from the Washington University School of Medicine and a bachelor’s degree in biology from Rice University. He is a diplomate of the American Board of Dermatology and a Fellow of the American Academy of Dermatology. He was an NIH GMA-1 study section member and a Zyma Foundation Visiting Scientist in Geneva.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,000 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.